Literature DB >> 19078739

Prolonged compound muscle action potential duration in critical illness myopathy: report of nine cases.

Edward J Park1, Takashi Nishida, Robert L Sufit, Michael M Minieka.   

Abstract

The objective of this study was to determine the diagnostic use of compound muscle action potential duration in patients with critical illness myopathy. Accurate diagnosis is important because the muscles recover once the offending agents are withdrawn. We retrospectively reviewed 9 cases seen at our institution between 1999 and 2003 in which critical illness myopathy was diagnosed on the basis of clinical and electrophysiological evaluations. All the patients had weakness, difficulty weaning from mechanical ventilation, sepsis, and exposure to intravenous corticosteroids in the intensive-care unit. Seventy-five percent of tested motor nerves had responses. Amplitude was decreased in 100% of ulnar and peroneal nerves, and 71% of median and tibial nerves. Duration was prolonged in 100% of responsive motor nerves. Prolonged compound muscle action potential duration was the most characteristic electrophysiological finding of critical illness myopathy. Its recognition as part of a quick and simple bedside diagnostic test makes it preferable to other tests.

Entities:  

Year:  2004        PMID: 19078739     DOI: 10.1097/01.cnd.0000126507.28097.16

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  2 in total

1.  Effect of membrane properties on skeletal muscle fiber excitability: a sensitivity analysis.

Authors:  Emma Fortune; Madeleine M Lowery
Journal:  Med Biol Eng Comput       Date:  2012-03-20       Impact factor: 2.602

2.  Feasibility and diagnostic accuracy of early electrophysiological recordings for ICU-acquired weakness: an observational cohort study.

Authors:  Luuk Wieske; Camiel Verhamme; Esther Witteveen; Aline Bouwes; Daniela S Dettling-Ihnenfeldt; Marike van der Schaaf; Marcus J Schultz; Ivo N van Schaik; Janneke Horn
Journal:  Neurocrit Care       Date:  2015-06       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.